Genetic Technologies announced this week that it has received its Clinical Laboratory Permit from the New York State Department of Health.
In late July, the DoH Clinical Laboratory Evaluation Program inspected the company's Melbourne laboratories; following the two-day audit, the company received a Laboratory Evaluation Report with "no significant deficiencies," allowing for the immediate issue of the permit.
This permit allows Genetic Technologies to meet requests received from New York physicians to provide the BREVAGen™ test to their patients and completes the out-of-state licensures that allows the company to provide testing services to all 50 U.S. states.
Having New York State as part of its territory will augment the current market adoption, which the company notes is delivering significant increases in the number of test samples provided to the laboratory during the current quarter to date.
"This is a wonderful endorsement of the quality of our laboratory systems and the validation package provided by our highly qualified staff," said Alison Mew, Genetic Technologies' CEO. "Importantly, it also allows women across the United States access to BREVAGen™ to deliver comprehensive breast health care."
For more information, visit gtglabs.com
Please see disclaimer on the MissionIR website